December 09, 2024 12:44 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Indian Foreign Secretary Vikram Misri reaches Dhaka, holds bilateral talks with Bangladeshi counterpart amid strained ties | AAP fields popular UPSC teacher Avadh Ojha from Delhi's Patparganj, Manish Sisodia shifted to Jangpura | Syria's unity, sovereignty and territorial integrity must be preserved: India | Serious allegations: Kiren Rijiju on 'Sonia Gandhi-George Soros link' | Delhi: Over 40 schools receive bomb threats, students sent back home; Kejriwal slams Amit Shah | 'Happy if she takes more responsibility': Supriya Sule on Mamata Banerjee expressing willingness to lead INDIA bloc | Rajnath Singh to visit Moscow to attend India-Russia Inter-Governmental Commission on Military and Military Technical Cooperation | Eknath Shinde wants home ministry in Mahayuti govt: Shiv Sena | Delhi businessman, returning from morning walk, shot dead by bike-borne men | Eight people killed in Kannauj bus accident, PM Modi announces compensation
Coronavirus Vaccine

Covaxin's approval premature, dangerous: Shashi Tharoor

| @indiablooms | Jan 03, 2021, at 08:34 pm

New Delhi/UNI: Congress leader and Thiruvananthapuram MP Shashi Tharoor on Sunday expressed apprehensions over the DCGI's nod for the emergency use of Bharat Biotech's COVID-19 vaccine 'Covaxin'.

In a tweet,  Tharoor said that the Covaxin has not completed its phase 3 trials.

"Approval was premature and could be dangerous. Dr Harsh Vardhan should please clarify," the parliamentarian averred.

Notably, the drug regulator's Subject Expert Committee (SEC) had on January 1 recommended the emergency use authorization to Serum Institute of India's Covishield and on January 2 recommended approval for both Bharat Biotech's Covaxin. The Drugs Controller General of India cleared both the vaccines for emergency approval today.

He further said that the use of Covaxin should be avoided till trials are completely over.

"India can start with the AstraZeneca vaccine in the meantime," he added.

The final decision to recommend Bharat Biotech's Covaxin after it presented updated data and justification and request for consideration of their proposal amid cases of mutant Coronavirus strain.

However, the SEC stated that the firm should continue with phase 3 clinical trial and submit the results emerging from the trial whenever available, sources said, reported the India Express.

 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.